Ian Hudson

Dr. Ian Hudson has a leading role on the team in areas that include optimizing clinical studies and strengthening regulatory systems in Africa and other low-resource regions, particularly for malaria, polio, and COVID-19 drugs.

Ian was a practicing pediatrician before joining SmithKline Beecham in 1989 to work in research and development. In 2001, he joined the UK government’s Medicines & Healthcare products Regulatory Service (MHRA), where he served as director of licensing and then CEO. Ian was the UK delegate to the scientific committee of the European Medicines Agency’s Management Board, CHMP, later becoming its vice chair. He was also an honorary senior lecturer in clinical pharmacology at the University of London and served as chair of the International Coalition of Medicines Regulatory Authorities.

Ian earned his medical degree, with a specialty in neonatal hematology, from London Hospital Medical College, and has postgraduate qualifications in pediatrics and pharmaceutical medicine. In 2020, he was awarded an OBE for Services to Healthcare, received a Faculty of Pharmaceutical Medicine President’s medal for contribution to pharmaceutical medicine, and was named a Global Fellow in Medicines Development by the International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine.